Familial Chylomicronemia Syndrome

Disease State Hub

FDA Alerts

FDA Alert

FDA Alert

FDA Grants Breakthrough Therapy Designation to Plozasiran for Familial Chylomicronemia Syndrome

01/13/2025

Miranda Manier, BA

Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome, earning FDA...

01/13/2025

Research Summaries

Research Summary

Physician pointing to a model of a pancreas

Research Summary

Key Differences Between Familial and Multifactorial Chylomicronemia Syndromes Identified

03/20/2025

Miranda Manier, BA

A recent study compared clinical and biochemical characteristics of patients with severe hypertriglyceridemia, distinguishing familial chylomicronemia syndrome from multifactorial chylomicronemia syndrome. ...

03/20/2025

Research Summary

Study: Olezarsen Reduces Triglycerides in Familial Chylomicronemia Syndrome

01/20/2025

Miranda Manier, BA

A phase 3 clinical trial demonstrates the efficacy of olezarsen in reducing plasma triglycerides and acute pancreatitis episodes in patients with familial chylomicronemia syndrome.

01/20/2025

FDA Alert

FDA Grants Breakthrough Therapy Designation to Plozasiran for Familial Chylomicronemia Syndrome

01/13/2025

Miranda Manier, BA

01/13/2025

Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

Dyslipidemia Screening and Management in Primary Care Practice: A Look Beyond the Numbers

09/07/2016

One-third of US adults have elevated low-density lipoprotein cholesterol levels, a condition that is most often diagnosed and treated in primary care. Appropriate screening helps identify these patients...

09/07/2016

March 2025

Current Issue

March 2025

Volume 65

Issue 3